We hypothesize that blockage of LAG-3 and PD-1 may improve PD-1 resistance for patients in whom PD-1 treatment is ineffective and tumors are drug-resistant; hence, LAG-3 and PD-1 blockage provides a potential new treatment approach for DLBCL. Here, LAG3 is linked to diffuse large B-cell lymphoma.